WestPark Capital Announces Closing of $5,700,000 Follow-On Offering & NASDAQ Up-listing of Lixte Biotechnology Holdings, Inc....
30 November 2020 - 9:52PM
Business Wire
WestPark Capital, Inc., a full-service investment bank and
securities broker-dealer, today announced the closing of the
follow-on offering for its client Lixte Biotechnology Holdings,
Inc. 1,200,000 units consisting of one share of common stock and
one warrant were sold for a total of $5,700,000 in gross proceeds.
Lixte Biotechnology Holdings, Inc. began trading on The Nasdaq
Capital Market ("Nasdaq") on Wednesday, November 25, 2020 under the
trading symbols "LIXT" and “LIXTW”.
WestPark Capital, Inc. acted as the book-running manager.
Lixte Biotechnology Holdings, Inc.’s registration statement
relating to the offering has been filed with, and declared
effective by, the United States Securities and Exchange
Commission.
The offering was made pursuant to an effective registration
statement on Form S-1 (No. 333-248588) previously filed with the
U.S. Securities and Exchange Commission (the "SEC") and declared
effective by the SEC on November 19, 2020. A final prospectus
describing the terms of the proposed offering was filed with the
SEC and may be obtained, when available, via the SEC's website at
www.sec.gov or from: WestPark Capital, Inc. - Attention: Jason
Stern, 1900 Avenue of the Stars, 3rd Floor, Los Angeles, CA 90077
or by Email: syndicate@wpcapital.com or by telephone at (310)
203-2919.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of that
state or jurisdiction.
About WestPark Capital, Inc.:
WestPark Capital is a full-service investment bank focused on
emerging growth sectors such as healthcare, software, technology,
biotechnology, financial services, manufacturing, consumer
products, media and telecom industries, among other categories.
WestPark Capital provides a comprehensive range of corporate
finance services, including initial public offerings, follow-on
offerings, private placements, CMPOs, RDs, ATM, SIPOs and corporate
finance advisory services. Additional information about WestPark
Capital is available at www.wpcapital.com or at
info@wpcapital.com.
About Lixte Biotechnology Holdings, Inc.
Lixte Biotechnology Holdings, Inc. is a drug discovery company
that uses biomarker technology to identify enzyme targets
associated with serious common diseases and then designs novel
compounds to attack those targets. Their product pipeline is
primarily focused on inhibitors of protein phosphatases, used alone
and in combination with cytotoxic agents and/or x-ray and immune
checkpoint blockers, and encompasses two major categories of
compounds at various stages of pre-clinical and clinical
development that they believe have broad therapeutic potential not
only for cancer but also for other debilitating and
life-threatening diseases. Additional information about Lixte
Biotechnology Holdings, Inc. is available at
eforman@lixte.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201130005903/en/
WestPark Capital, Inc. Attention: Jason Stern Email:
syndicate@wpcapital.com Phone: (310) 203-2919
Lixte Biotechnology (NASDAQ:LIXTW)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Lixte Biotechnology (NASDAQ:LIXTW)
Historical Stock Chart
Von Jul 2023 bis Jul 2024